Vildagliptin
Research & Development:
(Approved by Department of Scientific & Industrial Research, (DSIR))
Kimia Biosciences R&D is committed to research and development of improved generic drugs with the goal of addressing unmet patient needs with more meticulous resources and to establish a robust portfolio for a new generation of treatments. Kimia is committed to do significant investments in drug research and development in order to produce effective, safe and affordable medicines. Prucalopride Succinate
Infrastructure:
Kimia R&D has well equipped Analytical Lab, synthetic Lab and Intellectual property cell, where each scientist has access to Sci-finder search tools. Benfotiamine The Analytical Research lab comprises of HPLC, GC, GC-HS, Auto-Titrator, Polarimeter, UV spectrophotometer, IR spectrophotometer etc. There are dedicated hoods for each scientist in the synthetic lab with Rotavapours, Vacuum & Air dryers, cooling units, mechanical and magnetic stirrers, vacuum systems Instrumentation, scientific and analytical knowledge base at the R&D Centre facilitate:
- Impurity profiling for the APIs
- Development of Analytical methods and their validations
- Specifications from Raw materials to Non-pharmacopoeia Finished products.
- Accelerated and Real time stability studies
Expertise:
The expertise of R&D teams covers products across various therapeutic categories including Ant diabetics & Anti-hypertensive.
- Chiral chemistry
- Synthesizing building blocks
- Reactions: Pressure, Cryogenic, Metal hydride,Catalytic, Aliphatic-Aromatic-Heterocyclic, & Multi-step synthesis,
- Polymorphism
- Particle Size
- Bulk density
- Impurities synthesis
- Quality by Design approach
- DOE
Culture:
We are committed to create a culture of respect and dignity of each individual based on humanistic values at Kimiabiosciences where the individuality of each person is respected
R&D Scientists:
The team of Scientists at Kimia R&D involves people from diverse backgrounds who uses their vast experience & innovativeness and are determined to make Kimia R&D as an advance Centre for Research.
Speed:
Kimia strives hard and give their best to help meet customer deadlines with ICH quality products; the average time todevelop a process technology is 6-8 months
Quality
The Kimia R&D is committed to produce drugs of high quality based on principles of quality by design and ICH requirements
Innovation:
- Chiral reductions using homogeneous catalyst
- Chiral reduction using Enzymatic Technologies,
- Polymorphs Processes and Techniques,
- Process innovations to achieve benchmark costs
New products developed:
- Prucalopride succinate
- Acotiamide Hydrochloride trihydrate
- Fimasartan Potassium Hydrate
For More Info: https://www.kimiabiosciences.com/
#levosulpiridechemicalcompound #Pharmaceuticalcompaniesingurgaon #Teneligliptinapimanufacturersinindia #Genericonlinepharmacyindia #Kimiabiosciences #Pharmaceuticalcompanyinindia
Comments
Post a Comment